This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 114/13/1380    most recent CIRCULATIONAHA.106.620815v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexander, K. P. Search for Related Content PubMed PubMed Citation Articles by Alexander, K. P. Related Collections Cardiovascular Pharmacology Platelet function inhibitors Acute coronary syndromes Related Article

(Circulation. 2006;114:1380-1387.)
© 2006 American Heart Association, Inc.

Coronary Heart Disease

Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors

Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative

Karen P. Alexander, MD; Anita Y. Chen, MS; L. Kristin Newby, MD, MHS; Janice B. Schwartz, MD; Rita F. Redberg, MD; Judith S. Hochman, MD; Matthew T. Roe, MD, MHS; W. Brian Gibler, MD; E. Magnus Ohman, MD; Eric D. Peterson, MD, MPH, for the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators

From the Duke Clinical Research Institute (K.P.A., A.Y.C., L.K.N., M.T.R., E.M.O., E.D.P.), Duke University Medical Center, Durham, NC; University of California, San Francisco (J.B.S., R.F.R.), San Francisco; New York University School of Medicine (J.S.H.), New York; and University of Cincinnati College of Medicine (W.B.G.), Cincinnati, Ohio.

Correspondence to Karen P. Alexander, MD, DCRI, PO Box 17969, Durham, NC 27715. E-mail karen.alexander{at}duke.edu

Received February 13, 2006; revision received June 14, 2006; accepted June 23, 2006.

Background— Glycoprotein (GP) IIb/IIIa inhibitors are beneficial in patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS); their safe use in women, however, remains a concern. The contribution of dosing to the observed sex-related differences in bleeding is unknown.

Methods and Results— We explored the relationship between patient sex, GP IIb/IIIa inhibitor use, dose, and bleeding in 32 601 patients with NSTE ACS across 400 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) hospitals, of whom 18 436 were treated. GP IIb/IIIa inhibitor dose was defined as excessive if not reduced when creatinine clearance was <50 mL/min for eptifibatide or <30 mL/min for tirofiban. Major bleeding was defined as a hematocrit drop 0.12, need for transfusion, or intracranial bleeding. Major bleeding was adjusted for clinical factors and antithrombotic dose. The risk for bleeding attributable to excess GP IIb/IIIa dose was determined by sex using prevalence and adjusted odds ratios (ORs). Women had higher rates of major bleeding than men among those treated with GP IIb/IIIa inhibitors (15.7% versus 7.3%, P<0.0001) and among those not treated (8.5% versus 5.4%, P<0.0001). Despite similar serum creatinine levels, creatinine clearance averaged 20 points lower among treated women than men. Treated women were also more likely to receive excess GP IIb/IIIa doses than men (46.4% versus 17.2%, P<0.0001; adjusted OR 3.81, 95% confidence interval [CI] 3.39 to 4.27). Excess dosing was associated with increased risk of bleeding in women (OR 1.72, 95% CI 1.30 to 2.28) and men (OR 1.27, 95% CI 0.97 to 1.66); however, bleeding risk attributable to dosing was much higher in women (25.0% versus 4.4%).

Conclusions— Women experience more bleeding than men whether or not they are treated with GP IIb/IIIa inhibitors; however, because of frequent excessive dosing in women, up to one fourth of this sex-related risk difference in bleeding is avoidable. Appropriate dosing will improve care of all patients with NSTE ACS, with a particular benefit for women.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2006 114: 1343. [Extract] [Full Text]

This article has been cited by other articles:

				J. S. Berger, D. L. Bhatt, C. P. Cannon, Z. Chen, L. Jiang, J. B. Jones, S. R. Mehta, M. S. Sabatine, S. R. Steinhubl, E. J. Topol, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1935 - 1945. [Abstract] [Full Text] [PDF]

				L. J. Shaw, R. Bugiardini, and C. N. B. Merz Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1561 - 1575. [Abstract] [Full Text] [PDF]

				A. K. Jacobs The Efficacy of Drug-Eluting Stents in Women: A Window of Opportunity J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 611 - 613. [Full Text] [PDF]

				J. H. ALEXANDER The current state of antiplatelet therapy in acute coronary syndromes: The data and the real world Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_1): S16 - S23. [Abstract] [Full Text] [PDF]

				S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman, and M. S. Sabatine Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1195 - 1202. [Abstract] [Full Text] [PDF]

				E. Swahn, J. Alfredsson, R. Afzal, A. Budaj, S. Chrolavicius, K. Fox, S. Jolly, S. R. Mehta, R. de Winter, and S. Yusuf Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials Eur. Heart J., February 7, 2009; (2009) ehp009v1. [Abstract] [Full Text] [PDF]

				A. K. Jacobs Coronary Intervention in 2009: Are Women No Different Than Men? Circ Cardiovasc Interv, February 1, 2009; 2(1): 69 - 78. [Full Text] [PDF]

				WRITING GROUP MEMBERS, D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, et al. Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 27, 2009; 119(3): e21 - e181. [Full Text] [PDF]

				F. Latif, N. S. Kleiman, D. J. Cohen, M. J. Pencina, C.-H. Yen, D. E. Cutlip, D. J. Moliterno, D. Nassif, J. J. Lopez, J. F. Saucedo, et al. In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 37 - 45. [Abstract] [Full Text] [PDF]

				S. Husted Benefits and risks with antiplatelet therapy: how great a problem is bleeding? Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I19 - I24. [Abstract] [Full Text] [PDF]

				S. V. Rao, F.-S. Ou, T. Y. Wang, M. T. Roe, R. Brindis, J. S. Rumsfeld, and E. D. Peterson Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention: A Report From the National Cardiovascular Data Registry J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 379 - 386. [Abstract] [Full Text] [PDF]

				R. Matyal Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review Anesth. Analg., July 1, 2008; 107(1): 37 - 50. [Abstract] [Full Text] [PDF]

				S. S. Patel, H. Rana, and D. A. N. Mascarenhas Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93. [Abstract] [PDF]

				H. M. Krumholz and F. A. Masoudi The Year in Epidemiology, Health Services Research, and Outcomes Research J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2254 - 2262. [Full Text] [PDF]

				H. R. Reynolds, M. E. Farkouh, A. M. Lincoff, A. Hsu, E. Swahn, Z. P. Sadowski, J. A. White, E. J. Topol, J. S. Hochman, and for the GUSTO V Investigators Impact of Female Sex on Death and Bleeding After Fibrinolytic Treatment of Myocardial Infarction in GUSTO V Arch Intern Med, October 22, 2007; 167(19): 2054 - 2060. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]

				D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]

				R. A. Harrington Women, Acute Ischemic Heart Disease, and Antithrombotic Therapy: Challenges and Opportunities Circulation, June 5, 2007; 115(22): 2796 - 2798. [Full Text] [PDF]

				S. A. Spinler Managing acute coronary syndrome: Evidence-based approaches Am. J. Health Syst. Pharm., June 1, 2007; 64(11_Supplement_7): S14 - S24. [Abstract] [Full Text] [PDF]

				L. Pilote and for the GENESIS Investigators Sex-specific issues related to cardiovascular disease: a synopsis of the 2007 supplement Can. Med. Assoc. J., March 13, 2007; 176(6): 789 - 791. [Full Text] [PDF]

				J. A. Leopold Small-Molecule Glycoprotein IIb/IIIa Antagonists and Bleeding Risk in Women: Too Much of a Good Thing? Circulation, September 26, 2006; 114(13): 1344 - 1346. [Full Text] [PDF]